Similar to our previous study, we found that the TCRζ gene expression level in the CML group was significantly lower than that in healthy controls[2], and we further demonstrated that the TCRζ gene expression level may be increased in patients with CML who achieved complete remission. The gene discussed is CD247; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.